Definium Therapeutics, Inc. — Income Charts
12 quarters of history · ending 2023-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↓-14.0% -$147K
$905K
R&D↑+30.8% +$3M
$12M
D&A↑+0.0% +$0
$790K
Operating Income↓-27.3% -$5M
$-22M
EBITDA↑+0.0% +$0
$790K
Interest Expense
$439K
Other Income/Expense↑+1506.5% +$467K
$498K
Pretax Income↑+4.1% +$711K
$-16M
Tax Provision
$0
Net Income↓-8.7% -$1M
$-18M
Operating Margin↑+2858.9pts
-1858.6%
Net Margin↑+3038.1pts
-1541.1%
Effective Tax Rate↑+0.0pts
0.0%
ETR (Continuing Operations)
—
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)
—
Revenue YoY Variation
-14.0%
Income YoY Variation↓-28.7pts
-27.3%
Revenue QoQ Variation↓-214.4pts
-22.2%
Income QoQ Variation↑+26.2pts
25.9%